VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: Why is Vivimed Labs Ltd falling/rising?

As of 28-Jun, Vivimed Labs Ltd's stock price is falling, currently at 5.80, which reflects a decrease of 0.13 or 2.19%. The stock has underperformed compared to the benchmark Sensex, which has only declined by 0.40% over the past week, while Vivimed Labs has seen a more significant drop of 4.76%. Over the past month, the stock has decreased by 12.65%, contrasting sharply with the Sensex's increase of 0.80%. Year-to-date, Vivimed Labs has experienced a staggering decline of 67.10%, while the Sensex has only fallen by 9.53%.Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 22.07% against the 5-day average. This combination of poor performance relative to the market, declining investor interest, and trading below moving averages contributes to the ongoing decline in Vivimed Labs Ltd's stock price.

Q: Who are in the management team of Vivimed Labs.?

The management team of Vivimed Labs includes the following individuals:1. **Santosh Varalwar** - Managing Director2. **V Manohar Rao** - Whole Time Director3. **Subhash Varalwar** - Non Executive Director4. **Sandeep Varalwar** - Whole Time Director5. **S Raghunandan** - Whole Time Director6. **M Bhagvanth Rao** - Non Executive Independent Director7. **Nixon Patel** - Non Executive Independent Director8. **Umanath Varahabhotla** - Non Executive Independent Director9. **Yugandhar Kopparthi** - Company Secretary & Compliance OfficerThis team plays a crucial role in guiding the company’s strategic direction and operations.

Q: Who are the peers of the Vivimed Labs.?

Peers: The peers of Vivimed Labs. are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, Parabolic Drugs, ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form.Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, and Dr Reddy's Labs, while Below Average management risk is found at Vivimed Labs., ANG Lifesciences, and Deccan Healthcar. Growth is Excellent at Sun Pharma.Inds., Good at Dr Reddy's Labs, Average at Torrent Pharma, and Below Average at Divi's Lab., Cipla, Vivimed Labs., ANG Lifesciences, and Unick Fix-A-Form, with Parabolic Drugs not qualifying. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is seen at Vivimed Labs., ANG Lifesciences, and Unick Fix-A-Form, with Parabolic Drugs also not qualifying.Return Snapshot: Torrent Pharma has the highest 1-year return at 42.85%, while Cipla has the lowest at -8.67%. Vivimed Labs.' 1-year return is not available for comparison. Additionally, the six-month return is negative for Cipla and Dr Reddy's Labs.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.5 lacs (240.30%) Volume

Shareholding (Mar 2026)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.57%

Which are the latest news on Vivimed Labs.?

29-Jun-2026

Vivimed Labs Ltd is Rated Strong Sell
Vivimed Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

Why is Vivimed Labs Ltd falling/rising?

28-Jun-2026

As of 28-Jun, Vivimed Labs Ltd's stock price is at 5.80, reflecting a 2.19% decline and a significant year-to-date drop of 67.10%. The stock is underperforming compared to the Sensex and is trading below its moving averages, indicating a bearish trend and decreased investor interest.

View full answer

How big is Vivimed Labs.?

11-Jun-2026

As of 10th June, Vivimed Labs Ltd has a market capitalization of 53.00 Cr and reported Net Sales of 108.46 Cr, with a Net Profit loss of 45.41 Cr over the latest four quarters. As of March 2023, Shareholder's Funds were 39.42 Cr and Total Assets were 988.35 Cr.

View full answer

Who are in the management team of Vivimed Labs.?

11-Jun-2026

The management team of Vivimed Labs includes Santosh Varalwar (Managing Director), V Manohar Rao, Sandeep Varalwar, and S Raghunandan (Whole Time Directors), along with Subhash Varalwar (Non Executive Director), M Bhagvanth Rao, Nixon Patel, and Umanath Varahabhotla (Non Executive Independent Directors), and Yugandhar Kopparthi (Company Secretary & Compliance Officer). They are responsible for the company's strategic direction and operations.

View full answer

Who are the peers of the Vivimed Labs.?

11-Jun-2026

Vivimed Labs. peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Dr Reddy's Labs, Parabolic Drugs, ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form. Sun Pharma and Dr Reddy's Labs show excellent management and capital structures, while Vivimed Labs. has below average ratings in these areas and lacks a 1-year return for comparison.

View full answer

What does Vivimed Labs. do?

10-Jun-2026

Vivimed Labs Ltd manufactures specialty chemicals for the personal care, cosmetic, and pharmaceutical industries. As of December 2025, it reported net sales of 16 Cr and a net loss of 17 Cr, with a market cap of INR 53 Cr.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

31-May-2026

When is the next results date for Vivimed Labs Ltd?

27-May-2026

The next results date for Vivimed Labs Ltd is 30 May 2026.

View full answer

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With HIgh Debt (Debt-Equity Ratio at 9.51 times)- the company has a Weak Long Term Fundamental Strength

Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.02 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Flat results in Dec 25

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 47 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

1.23

Revenue and Profits:

Net Sales:

16 Cr

(Quarterly Results - Dec 2025)

Net Profit:

-17 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.5%

6 Months

-69.26%

1 Year

0.0%

2 Years

0.0%

3 Years

4.35%

4 Years

-40.83%

5 Years

-77.19%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Locks at Upper Circuit With 4.9% Gain — Buyers Queue, Sellers Absent

At Rs 5.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.9% on 29 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Vivimed Labs Ltd is Rated Strong Sell

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 May 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis presented here is based on the company’s current fundamentals, returns, and financial metrics as of 18 June 2026, providing investors with an up-to-date perspective on the stock’s position.

Read full news article

Vivimed Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

At Rs 6.08, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 5% on 8 Jun 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance between supply and demand.

Read full news article

Announcements

Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)

17-Jun-2026 | Source : BSE

form G

Board Meeting Postponed

30-May-2026 | Source : BSE

Board meeting Postponed

Update on board meeting

26-May-2026 | Source : BSE

The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.78

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

15.18%

Institutional Holding

1.76%

ROCE (avg)

-1.91%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.23

EV to EBIT

-13.23

EV to EBITDA

-37.97

EV to Capital Employed

1.02

EV to Sales

3.90

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

15.1806

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Varalwar Sandeep (2.81%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

68.75%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.63",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.22",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.94",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-16.57",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.27",
          "val2": "187.10",
          "chgp": "-37.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.05",
          "val2": "-187.30",
          "chgp": "93.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.95",
          "val2": "35.90",
          "chgp": "-91.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.96",
          "val2": "-328.53",
          "chgp": "90.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11.22%",
          "val2": "-100.11%",
          "chgp": "88.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Change(%)

Net Sales

11.63

Operating Profit (PBDIT) excl Other Income

-11.22

Interest

0.94

Exceptional Items

0.00

Standalone Net Profit

-16.57

Operating Profit Margin (Excl OI)

-96.47%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'23

Change(%)

Net Sales

116.27

187.10

-37.86%

Operating Profit (PBDIT) excl Other Income

-13.05

-187.30

93.03%

Interest

2.95

35.90

-91.78%

Exceptional Items

0.00

Consolidate Net Profit

-31.96

-328.53

90.27%

Operating Profit Margin (Excl OI)

-11.22%

-100.11%

88.89%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad